Skip to main content
SpringerLink
Log in

Control of cancer pain often inadequate despite effective drugs and guidelines

  • Disease Management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Ripamonti C, Dickerson ED. Strategies for the treatment of cancer pain in the new millennium. Drugs 2001; 61 (7): 955–77

    Article  PubMed  CAS  Google Scholar 

  2. Daut RL, Cleeland CS. The prevalence and severity of pain in cancer. Cancer 1982; 50: 1913–8

    Article  PubMed  CAS  Google Scholar 

  3. World Health Organization: cancer pain relief. Geneva: WHO Office of Publication, 1986

    Google Scholar 

  4. World Health Organization: cancer pain relief. 2nd ed. Geneva: WHO Office of Publication, 1996

    Google Scholar 

  5. British National Formulary. No. 41. London: British Medical Association and Royal Pharmaceutical Society of Great Britain, 2001 Mar

  6. 2001 Drug Topics Red Book. Montvale (NJ): Medical Economics Company, Inc., 2001

  7. Zech DFJ, Grond S, Lynch J, et al. Validation of the World Health Organisation guidelines for cancer pain relief. A 10-year prospective study. Pain 1995; 63: 65–76

    Article  PubMed  CAS  Google Scholar 

  8. Grossman SA, Sheidler VR, Sweeden K, et al. Correlation of patient and care giver ratings of cancer pain. J Pain Symptom Manage 1991; 6: 53–7

    Article  PubMed  CAS  Google Scholar 

  9. Larue F, Colleau SM, Fontaine AL, et al. Oncologists and primary care physicians’ attitudes toward pain control and morphine prescribing in France. Cancer 1995; 76: 2375–82

    Article  PubMed  CAS  Google Scholar 

  10. Drexel H, Dzien A, Spiegel RW, et al. Treatment of severe cancer pain by low-dose continuous subcutaneous morphine. Pain 1989; 36: 169–76

    Article  PubMed  CAS  Google Scholar 

  11. Kalso E, Heiskanen T, Rantio M, et al. Epidural and subcutaneous morphine in the management of cancer pain: a double-blind cross-over study. Pain 1996; 67: 443–9

    Article  PubMed  CAS  Google Scholar 

  12. Bennett GJ. Update on the neurophysiology of pain transmission and modulation: focus on the NMDA-Receptor. J Pain Symptom Manage 2000; 19: S2–S6

    Article  PubMed  CAS  Google Scholar 

  13. Morley JS, Makin MK. The use of methadone in cancer pain poorly responsive to other opioids. Pain Rev 1998; 5: 51–8

    Article  CAS  Google Scholar 

  14. Ripamonti C, Zecca E, Bruera E. An update on the clinical use of methadone for cancer pain. Pain 1997; 70: 109–15

    Article  PubMed  CAS  Google Scholar 

  15. Ripamonti C, Groff L, Brunelli C, et al. Switching from morphine to oral methadone in treating cancer pain: what is the equianalgesic dose ratio? J Clin Oncol 1998; 16 (10): 3216–21

    PubMed  CAS  Google Scholar 

  16. Fine PG. Breakthrough cancer pain: epidemiology, characteristics and management. CNS Drugs 2000 May; 13 (5): 313–9

    Article  Google Scholar 

  17. Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain 1990; 41: 273–81

    Article  PubMed  CAS  Google Scholar 

  18. Robison JM, Wilkie DJ, Campbell B. Sublingual and oral morphine administration. Nurs Clin North Am 1995; 30: 725–43

    PubMed  CAS  Google Scholar 

  19. Streisand JB, Busch MA, Egan TD, et al. Dose proportionality and pharmacokinetics of oral transmucosal fentanyl citrate. Anesthesiology 1998; 88: 305–9

    Article  PubMed  CAS  Google Scholar 

  20. Patt RB. Long-term safety and efficacy of oral transmucosal fentanyl citrate (OTFC, Actiq™) for treatment of breakthrough cancer pain [abstract]. 16th Annual Scientific Meeting, American Pain Society: 1997 Oct 23–26; New Orleans

    Google Scholar 

  21. Caraceni A, Portenoy RK, and a Working Group of the IASP Task Force on Cancer Pain. An international survey of cancer pain characteristics and syndromes. Pain 1999; 82: 263–74

    Article  PubMed  CAS  Google Scholar 

  22. Sindrup SH, Jensen TS. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain 1999; 83: 389–400

    Article  PubMed  CAS  Google Scholar 

  23. Caruso FS. MorphiDex pharmacokinetic studies and single-dose analgesic efficacy studies in patients with postoperative pain. JPSM 2000; 19: S31–S36

    CAS  Google Scholar 

  24. Yang CY, Wong CS, Chang JY, et al. Intrathecal ketamine reduces morphine requirements in patients with terminal cancer. Can J Anaesth 1996; 43 (4): 379–83

    Article  PubMed  CAS  Google Scholar 

  25. Eisenach JC, Du Pen S, Dubois M, et al. Epidural Clonidine analgesia for intractable cancer pain. Pain 1995; 61: 391–9

    Article  PubMed  CAS  Google Scholar 

  26. Glynn C, Dawson D, Sanders RA. A double-blind comparison between epidural morphine and epidural Clonidine in patients with chronic non-cancer pain. Pain 1988; 34: 123–8

    Article  PubMed  CAS  Google Scholar 

  27. Caraceni A, Zecca E, Martini C, et al. Gabapentin as an adjuvant to opioid analgesia for neuropathic cancer pain. JPSM 1999; 17: 441–52

    CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Control of cancer pain often inadequate despite effective drugs and guidelines. Drugs Ther. Perspect 18, 11–15 (2002). https://doi.org/10.2165/00042310-200218020-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200218020-00005

Keywords

Search

Navigation